Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.
Identifieur interne : 002665 ( Main/Exploration ); précédent : 002664; suivant : 002666Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.
Auteurs : David Langleben [Canada] ; Nazzareno Galiè [Italie] ; Jianguo He [République populaire de Chine] ; Yigao Huang [République populaire de Chine] ; Marc Humbert [France] ; Anne Keogh [Australie] ; Lewis J. Rubin [États-Unis] ; Daxin Zhou [République populaire de Chine] ; John Curram [Royaume-Uni] ; Neil Davie [Allemagne] ; Hossein-Ardeschir Ghofrani [Royaume-Uni]Source :
- The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation [ 1557-3117 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Femelle, Fonction ventriculaire droite (), Fonction ventriculaire droite (physiologie), Humains, Hypertension pulmonaire (physiopathologie), Hypertension pulmonaire (traitement médicamenteux), Marche à pied (physiologie), Mâle, Méthode en double aveugle, Pression ventriculaire (), Pyrazoles (administration et posologie), Pyrimidines (administration et posologie), Relation dose-effet des médicaments, Résultat thérapeutique, Épreuve d'effort (), Études de suivi.
- MESH :
- administration et posologie : Pyrazoles, Pyrimidines.
- physiologie : Fonction ventriculaire droite, Marche à pied.
- physiopathologie : Hypertension pulmonaire.
- traitement médicamenteux : Hypertension pulmonaire.
- Adulte d'âge moyen, Femelle, Fonction ventriculaire droite, Humains, Mâle, Méthode en double aveugle, Pression ventriculaire, Relation dose-effet des médicaments, Résultat thérapeutique, Épreuve d'effort, Études de suivi.
English descriptors
- KwdEn :
- Dose-Response Relationship, Drug, Double-Blind Method, Exercise Test (drug effects), Female, Follow-Up Studies, Humans, Hypertension, Pulmonary (drug therapy), Hypertension, Pulmonary (physiopathology), Male, Middle Aged, Pyrazoles (administration & dosage), Pyrimidines (administration & dosage), Treatment Outcome, Ventricular Function, Right (drug effects), Ventricular Function, Right (physiology), Ventricular Pressure (drug effects), Walking (physiology).
- MESH :
- chemical , administration & dosage : Pyrazoles, Pyrimidines.
- drug effects : Exercise Test, Ventricular Function, Right, Ventricular Pressure.
- drug therapy : Hypertension, Pulmonary.
- physiology : Ventricular Function, Right, Walking.
- physiopathology : Hypertension, Pulmonary.
- Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
In PATENT-1, riociguat significantly improved 6-minute walking distance (6MWD) and a range of secondary end-points in patients with pulmonary arterial hypertension (PAH). We investigated whether riociguat increased the proportion of patients achieving clinically relevant responder thresholds compared with placebo during PATENT-1.
DOI: 10.1016/j.healun.2014.12.001
PubMed: 25703961
Affiliations:
- Allemagne, Australie, Canada, France, Italie, Royaume-Uni, République populaire de Chine, États-Unis
- Angleterre, Californie, Grand Londres, Québec, Île-de-France
- Londres, Montréal, Orsay, Pékin
- Université McGill, Université Paris-Sud
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002F35
- to stream PubMed, to step Curation: 002E57
- to stream PubMed, to step Checkpoint: 002E57
- to stream Ncbi, to step Merge: 002277
- to stream Ncbi, to step Curation: 002277
- to stream Ncbi, to step Checkpoint: 002277
- to stream Main, to step Merge: 002665
- to stream Main, to step Curation: 002665
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.</title><author><name sortKey="Langleben, David" sort="Langleben, David" uniqKey="Langleben D" first="David" last="Langleben">David Langleben</name><affiliation wicri:level="4"><nlm:affiliation>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Canada. Electronic address: david.langleben@mcgill.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region><settlement type="city">Montréal</settlement></placeName><orgName type="university">Université McGill</orgName></affiliation></author><author><name sortKey="Galie, Nazzareno" sort="Galie, Nazzareno" uniqKey="Galie N" first="Nazzareno" last="Galiè">Nazzareno Galiè</name><affiliation wicri:level="1"><nlm:affiliation>Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Hospital, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Hospital, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="He, Jianguo" sort="He, Jianguo" uniqKey="He J" first="Jianguo" last="He">Jianguo He</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Huang, Yigao" sort="Huang, Yigao" uniqKey="Huang Y" first="Yigao" last="Huang">Yigao Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Guangdong General Hospital and Guangdong Cardiovascular Institute, Guangzhou, Guangdong, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Cardiology, Guangdong General Hospital and Guangdong Cardiovascular Institute, Guangzhou, Guangdong</wicri:regionArea><wicri:noRegion>Guangdong</wicri:noRegion></affiliation></author><author><name sortKey="Humbert, Marc" sort="Humbert, Marc" uniqKey="Humbert M" first="Marc" last="Humbert">Marc Humbert</name><affiliation wicri:level="4"><nlm:affiliation>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin-Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin-Bicêtre</wicri:regionArea><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Keogh, Anne" sort="Keogh, Anne" uniqKey="Keogh A" first="Anne" last="Keogh">Anne Keogh</name><affiliation wicri:level="1"><nlm:affiliation>St Vincent's Hospital, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St Vincent's Hospital, Sydney, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Rubin, Lewis J" sort="Rubin, Lewis J" uniqKey="Rubin L" first="Lewis J" last="Rubin">Lewis J. Rubin</name><affiliation wicri:level="2"><nlm:affiliation>University of California, San Diego, La Jolla, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>University of California, San Diego, La Jolla</wicri:cityArea></affiliation></author><author><name sortKey="Zhou, Daxin" sort="Zhou, Daxin" uniqKey="Zhou D" first="Daxin" last="Zhou">Daxin Zhou</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Curram, John" sort="Curram, John" uniqKey="Curram J" first="John" last="Curram">John Curram</name><affiliation wicri:level="1"><nlm:affiliation>Global Development, Bayer Pharma AG, Newbury, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Global Development, Bayer Pharma AG, Newbury</wicri:regionArea><wicri:noRegion>Newbury</wicri:noRegion></affiliation></author><author><name sortKey="Davie, Neil" sort="Davie, Neil" uniqKey="Davie N" first="Neil" last="Davie">Neil Davie</name><affiliation wicri:level="1"><nlm:affiliation>Global Clinical Development, Bayer Pharma AG, Wuppertal, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Global Clinical Development, Bayer Pharma AG, Wuppertal</wicri:regionArea><wicri:noRegion>Wuppertal</wicri:noRegion><wicri:noRegion>Wuppertal</wicri:noRegion><wicri:noRegion>Wuppertal</wicri:noRegion></affiliation></author><author><name sortKey="Ghofrani, Hossein Ardeschir" sort="Ghofrani, Hossein Ardeschir" uniqKey="Ghofrani H" first="Hossein-Ardeschir" last="Ghofrani">Hossein-Ardeschir Ghofrani</name><affiliation wicri:level="3"><nlm:affiliation>University of Giessen and Marburg Lung Center, Giessen, Germany, German Center of Lung Research, and Department of Medicine, Imperial College London, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Giessen and Marburg Lung Center, Giessen, Germany, German Center of Lung Research, and Department of Medicine, Imperial College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25703961</idno><idno type="pmid">25703961</idno><idno type="doi">10.1016/j.healun.2014.12.001</idno><idno type="wicri:Area/PubMed/Corpus">002F35</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002F35</idno><idno type="wicri:Area/PubMed/Curation">002E57</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002E57</idno><idno type="wicri:Area/PubMed/Checkpoint">002E57</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002E57</idno><idno type="wicri:Area/Ncbi/Merge">002277</idno><idno type="wicri:Area/Ncbi/Curation">002277</idno><idno type="wicri:Area/Ncbi/Checkpoint">002277</idno><idno type="wicri:Area/Main/Merge">002665</idno><idno type="wicri:Area/Main/Curation">002665</idno><idno type="wicri:Area/Main/Exploration">002665</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.</title><author><name sortKey="Langleben, David" sort="Langleben, David" uniqKey="Langleben D" first="David" last="Langleben">David Langleben</name><affiliation wicri:level="4"><nlm:affiliation>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Canada. Electronic address: david.langleben@mcgill.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal</wicri:regionArea><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region><settlement type="city">Montréal</settlement></placeName><orgName type="university">Université McGill</orgName></affiliation></author><author><name sortKey="Galie, Nazzareno" sort="Galie, Nazzareno" uniqKey="Galie N" first="Nazzareno" last="Galiè">Nazzareno Galiè</name><affiliation wicri:level="1"><nlm:affiliation>Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Hospital, Bologna, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Hospital, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="He, Jianguo" sort="He, Jianguo" uniqKey="He J" first="Jianguo" last="He">Jianguo He</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Huang, Yigao" sort="Huang, Yigao" uniqKey="Huang Y" first="Yigao" last="Huang">Yigao Huang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Guangdong General Hospital and Guangdong Cardiovascular Institute, Guangzhou, Guangdong, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Cardiology, Guangdong General Hospital and Guangdong Cardiovascular Institute, Guangzhou, Guangdong</wicri:regionArea><wicri:noRegion>Guangdong</wicri:noRegion></affiliation></author><author><name sortKey="Humbert, Marc" sort="Humbert, Marc" uniqKey="Humbert M" first="Marc" last="Humbert">Marc Humbert</name><affiliation wicri:level="4"><nlm:affiliation>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin-Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Le Kremlin-Bicêtre</wicri:regionArea><wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Keogh, Anne" sort="Keogh, Anne" uniqKey="Keogh A" first="Anne" last="Keogh">Anne Keogh</name><affiliation wicri:level="1"><nlm:affiliation>St Vincent's Hospital, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St Vincent's Hospital, Sydney, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Rubin, Lewis J" sort="Rubin, Lewis J" uniqKey="Rubin L" first="Lewis J" last="Rubin">Lewis J. Rubin</name><affiliation wicri:level="2"><nlm:affiliation>University of California, San Diego, La Jolla, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>University of California, San Diego, La Jolla</wicri:cityArea></affiliation></author><author><name sortKey="Zhou, Daxin" sort="Zhou, Daxin" uniqKey="Zhou D" first="Daxin" last="Zhou">Daxin Zhou</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Curram, John" sort="Curram, John" uniqKey="Curram J" first="John" last="Curram">John Curram</name><affiliation wicri:level="1"><nlm:affiliation>Global Development, Bayer Pharma AG, Newbury, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Global Development, Bayer Pharma AG, Newbury</wicri:regionArea><wicri:noRegion>Newbury</wicri:noRegion></affiliation></author><author><name sortKey="Davie, Neil" sort="Davie, Neil" uniqKey="Davie N" first="Neil" last="Davie">Neil Davie</name><affiliation wicri:level="1"><nlm:affiliation>Global Clinical Development, Bayer Pharma AG, Wuppertal, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Global Clinical Development, Bayer Pharma AG, Wuppertal</wicri:regionArea><wicri:noRegion>Wuppertal</wicri:noRegion><wicri:noRegion>Wuppertal</wicri:noRegion><wicri:noRegion>Wuppertal</wicri:noRegion></affiliation></author><author><name sortKey="Ghofrani, Hossein Ardeschir" sort="Ghofrani, Hossein Ardeschir" uniqKey="Ghofrani H" first="Hossein-Ardeschir" last="Ghofrani">Hossein-Ardeschir Ghofrani</name><affiliation wicri:level="3"><nlm:affiliation>University of Giessen and Marburg Lung Center, Giessen, Germany, German Center of Lung Research, and Department of Medicine, Imperial College London, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Giessen and Marburg Lung Center, Giessen, Germany, German Center of Lung Research, and Department of Medicine, Imperial College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><series><title level="j">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</title><idno type="eISSN">1557-3117</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Exercise Test (drug effects)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Hypertension, Pulmonary (drug therapy)</term><term>Hypertension, Pulmonary (physiopathology)</term><term>Male</term><term>Middle Aged</term><term>Pyrazoles (administration & dosage)</term><term>Pyrimidines (administration & dosage)</term><term>Treatment Outcome</term><term>Ventricular Function, Right (drug effects)</term><term>Ventricular Function, Right (physiology)</term><term>Ventricular Pressure (drug effects)</term><term>Walking (physiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Fonction ventriculaire droite ()</term><term>Fonction ventriculaire droite (physiologie)</term><term>Humains</term><term>Hypertension pulmonaire (physiopathologie)</term><term>Hypertension pulmonaire (traitement médicamenteux)</term><term>Marche à pied (physiologie)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Pression ventriculaire ()</term><term>Pyrazoles (administration et posologie)</term><term>Pyrimidines (administration et posologie)</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Épreuve d'effort ()</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Pyrazoles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Pyrazoles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Exercise Test</term><term>Ventricular Function, Right</term><term>Ventricular Pressure</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypertension, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Fonction ventriculaire droite</term><term>Marche à pied</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Ventricular Function, Right</term><term>Walking</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Hypertension pulmonaire</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hypertension, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hypertension pulmonaire</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Fonction ventriculaire droite</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Pression ventriculaire</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term><term>Épreuve d'effort</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In PATENT-1, riociguat significantly improved 6-minute walking distance (6MWD) and a range of secondary end-points in patients with pulmonary arterial hypertension (PAH). We investigated whether riociguat increased the proportion of patients achieving clinically relevant responder thresholds compared with placebo during PATENT-1.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>République populaire de Chine</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Californie</li><li>Grand Londres</li><li>Québec</li><li>Île-de-France</li></region><settlement><li>Londres</li><li>Montréal</li><li>Orsay</li><li>Pékin</li></settlement><orgName><li>Université McGill</li><li>Université Paris-Sud</li></orgName></list><tree><country name="Canada"><region name="Québec"><name sortKey="Langleben, David" sort="Langleben, David" uniqKey="Langleben D" first="David" last="Langleben">David Langleben</name></region></country><country name="Italie"><noRegion><name sortKey="Galie, Nazzareno" sort="Galie, Nazzareno" uniqKey="Galie N" first="Nazzareno" last="Galiè">Nazzareno Galiè</name></noRegion></country><country name="République populaire de Chine"><noRegion><name sortKey="He, Jianguo" sort="He, Jianguo" uniqKey="He J" first="Jianguo" last="He">Jianguo He</name></noRegion><name sortKey="Huang, Yigao" sort="Huang, Yigao" uniqKey="Huang Y" first="Yigao" last="Huang">Yigao Huang</name><name sortKey="Zhou, Daxin" sort="Zhou, Daxin" uniqKey="Zhou D" first="Daxin" last="Zhou">Daxin Zhou</name></country><country name="France"><region name="Île-de-France"><name sortKey="Humbert, Marc" sort="Humbert, Marc" uniqKey="Humbert M" first="Marc" last="Humbert">Marc Humbert</name></region></country><country name="Australie"><noRegion><name sortKey="Keogh, Anne" sort="Keogh, Anne" uniqKey="Keogh A" first="Anne" last="Keogh">Anne Keogh</name></noRegion></country><country name="États-Unis"><region name="Californie"><name sortKey="Rubin, Lewis J" sort="Rubin, Lewis J" uniqKey="Rubin L" first="Lewis J" last="Rubin">Lewis J. Rubin</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Curram, John" sort="Curram, John" uniqKey="Curram J" first="John" last="Curram">John Curram</name></noRegion><name sortKey="Ghofrani, Hossein Ardeschir" sort="Ghofrani, Hossein Ardeschir" uniqKey="Ghofrani H" first="Hossein-Ardeschir" last="Ghofrani">Hossein-Ardeschir Ghofrani</name></country><country name="Allemagne"><noRegion><name sortKey="Davie, Neil" sort="Davie, Neil" uniqKey="Davie N" first="Neil" last="Davie">Neil Davie</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002665 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002665 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25703961
|texte= Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25703961" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |